$KRYS (+0,21%)

Krystal Biotech, Inc. ( KRYS ) announced fourth quarter earnings that were up from the same period last year

The company's net income totaled $45.48 million, or $1.52 per share. In the previous year, it amounted to 8.69 million US dollars or 0.30 US dollars per share.

The company's turnover increased by 116.3 % from 42.14 million US dollars in the previous year to 91.14 million US dollars in this period.

The results of Krystal Biotech, Inc. at a glance (GAAP):

-Profit: $45.48 million compared to $8.69 million last year.

-EPS: $1.52 vs. $0.30 last year.

-Revenue: $91.14 million compared to $42.14 million last year.

https://ir.krystalbio.com/news-releases/news-release-details/krystal-biotech-announces-fourth-quarter-and-full-year-2024

https://www.rttnews.com/3514054/krystal-biotech-inc-bottom-line-advances-in-q4.aspx

$KRYS (+0,21%)

Summary

• Krystal Biotech's VYJUVEK, a breakthrough gene therapy for DEB, generated revenues of $83.8m in 3Q 2024, doubling from 4Q 2023.
• At 57x 2024 earnings, Krystal's stock appears expensive but is expected to double in earnings by 2025.
• With the upcoming expansion of the EU and Japan market, Krystal seems poised to exceed analysts' growth expectations.
• VYJUVEK is a potential blockbuster as Krystal targets $1 billion in sales with its first commercialized drug.
• Krystal is capitalizing on its niche in redosable gene therapy with a compelling pipeline focused on multiple genetic diseases.

Krystal Biotech: Blockbuster-Ambitionen für topische Gentherapie (NASDAQ:KRYS) | Auf der Suche nach Alpha

As I already have Vertex $VRTX (+0,64%) already in my portfolio, I will simply buy the competitor after the good quarterly figures. Perhaps there will be a takeover.

https://www.marketbeat.com/instant-alerts/nasdaq-krys-boost-price-target-2024-11-05/